Skip to main page content
U.S. flag

An official website of the United States government

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Search Results

218 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
ROS1 and ALK fusions in colorectal cancer, with evidence of intratumoral heterogeneity for molecular drivers.
Aisner DL, Nguyen TT, Paskulin DD, Le AT, Haney J, Schulte N, Chionh F, Hardingham J, Mariadason J, Tebbutt N, Doebele RC, Weickhardt AJ, Varella-Garcia M. Aisner DL, et al. Among authors: tebbutt n. Mol Cancer Res. 2014 Jan;12(1):111-8. doi: 10.1158/1541-7786.MCR-13-0479-T. Epub 2013 Dec 2. Mol Cancer Res. 2014. PMID: 24296758 Free PMC article. Clinical Trial.
Biomarkers of 5-FU response in colon cancer.
Mariadason JM, Tebbutt NC. Mariadason JM, et al. Cancer Biol Ther. 2011 Apr 15;11(8):771-2. doi: 10.4161/cbt.11.8.15109. Epub 2011 Apr 15. Cancer Biol Ther. 2011. PMID: 21343696 Free article. No abstract available.
Impact of KRAS and BRAF Gene Mutation Status on Outcomes From the Phase III AGITG MAX Trial of Capecitabine Alone or in Combination With Bevacizumab and Mitomycin in Advanced Colorectal Cancer.
Price TJ, Hardingham JE, Lee CK, Weickhardt A, Townsend AR, Wrin JW, Chua A, Shivasami A, Cummins MM, Murone C, Tebbutt NC. Price TJ, et al. J Clin Oncol. 2011 Jul 1;29(19):2675-82. doi: 10.1200/JCO.2010.34.5520. Epub 2011 Jun 6. J Clin Oncol. 2011. PMID: 21646616 Clinical Trial.
Dual targeting of the epidermal growth factor receptor using the combination of cetuximab and erlotinib: preclinical evaluation and results of the phase II DUX study in chemotherapy-refractory, advanced colorectal cancer.
Weickhardt AJ, Price TJ, Chong G, Gebski V, Pavlakis N, Johns TG, Azad A, Skrinos E, Fluck K, Dobrovic A, Salemi R, Scott AM, Mariadason JM, Tebbutt NC. Weickhardt AJ, et al. Among authors: tebbutt nc. J Clin Oncol. 2012 May 1;30(13):1505-12. doi: 10.1200/JCO.2011.38.6599. Epub 2012 Mar 12. J Clin Oncol. 2012. PMID: 22412142 Clinical Trial.
Correlation of extended RAS and PIK3CA gene mutation status with outcomes from the phase III AGITG MAX STUDY involving capecitabine alone or in combination with bevacizumab plus or minus mitomycin C in advanced colorectal cancer.
Price TJ, Bruhn MA, Lee CK, Hardingham JE, Townsend AR, Mann KP, Simes J, Weickhardt A, Wrin JW, Wilson K, Gebski V, Van Hazel G, Robinson B, Cunningham D, Tebbutt NC. Price TJ, et al. Among authors: tebbutt nc. Br J Cancer. 2015 Mar 17;112(6):963-70. doi: 10.1038/bjc.2015.37. Br J Cancer. 2015. PMID: 25742472 Free PMC article. Clinical Trial.
Vascular endothelial growth factor D expression is a potential biomarker of bevacizumab benefit in colorectal cancer.
Weickhardt AJ, Williams DS, Lee CK, Chionh F, Simes J, Murone C, Wilson K, Parry MM, Asadi K, Scott AM, Punt CJ, Nagtegaal ID, Price TJ, Mariadason JM, Tebbutt NC. Weickhardt AJ, et al. Among authors: tebbutt nc. Br J Cancer. 2015 Jun 30;113(1):37-45. doi: 10.1038/bjc.2015.209. Br J Cancer. 2015. PMID: 26125443 Free PMC article. Clinical Trial.
218 results